A federal judge has dismissed claims that GlaxoSmithKline delayed the entry of generic versions of its antidepressant Wellbutrin XL. Plaintiffs in the antitrust litigation allege that the pharmaceutical giant entered into illegal agreements with generic drug makers to settle patent infringement lawsuits.

U.S. District Judge Mary A. McLaughlin of the Eastern District of Pennsylvania granted GSK's motion for summary judgment. Direct and indirect purchasers of Wellbutrin initiated the suit in 2008. Those plaintiffs argued the Wellbutrin settlement was anti-competitive in nature.

GSK is represented by Stephen Kastenberg, Leslie John, Ed Rogers, Jason Leckerman, Jessica Anthony, Marcel Pratt and Barbara Schwartz of Ballard Spahr LLP.

Related Practice

Antitrust